CareDx stock rockets 22% after blowout quarter and big guidance hike, extending a nearly 500% one-year run. The transplant diagnostics company reported stronger-than-expected third-quarter revenue and earnings, while testing volumes rose following its Naveris acquisition. Published 11/03/26 AT 1:10 AM AEDT Shares of CareDx soared more than 22% on Friday after the transplant diagnostics company reported third-quarter results that far exceeded Wall Street's expectations and sharply raised its full-year outlook. CareDx stock jumped $15.89, or 22.22%, to close at $87.41. The shares opened at $80.62, up from Thursday's close of $71.52, and climbed as high as about $90.87 during the session. Trading volume reached about 3.56 million shares, nearly three times the stock's three-month average of about 1.31 million. The company's market value rose to about $4.6 billion. The rally came on a difficult day for the broader market, when the S&P 500 fell 1.82% amid a sell-off in technology stocks. A big beat CareDx reported third-quarter revenue of $139.4 million, up 39% from a year earlier and well above analysts' expectations of about $122 million. Adjusted earnings came in at 70 cents per share, far ahead of the consensus estimate of about 25 cents. On a GAAP basis, earnings rose to 35 cents per share from 3 cents a year earlier. Earnings before interest, taxes, depreciation and amortization doubled to $30 million. The company also generated $13 million in cash flow from operations. Testing volumes surge The growth was driven by CareDx's testing services business, where revenue jumped 65% to $119 million. Testing volumes climbed 51% to about 75,900, boosted by the company's acquisition in July of Naveris, a maker of cancer blood tests. The deal has expanded CareDx's reach into specialty oncology, beyond its core business of monitoring transplant patients for signs of organ rejection. CareDx's patient and digital solutions revenue rose 31% to $20 million, helped by growth in its pharmacy services. Guidance raised The company lifted its outlook for the year. CareDx now expects 2026 revenue of $520 million to $530 million, up from its previous forecast of $490 million to $500 million and above the Wall Street consensus of about $495 million. It also raised its adjusted EBITDA target to $90 million to $100 million, from a prior range of $66 million to $78 million. Chief Executive John Hanna said growing clinical interest in how molecular information can guide patient care is fueling demand. "We believe these dynamics create meaningful opportunities for continued profitable growth," he said. Clinical data adds support Investors also responded to new clinical data. At the American Society of Nephrology's Kidney Week 2026, CareDx presented multinational data on its AlloSure Kidney and AlloSure Plus tests, which help detect signs of transplant rejection. Analysts said the data strengthened the case for long-term demand for the company's transplant testing services. Analyst targets trail the stock Several analysts raised their price targets before the rally. Canaccord Genuity lifted its target to $80 from $65, and BTIG set a target of $81, both with buy ratings. After Friday's surge, the stock is now trading above both targets, suggesting analysts may need to revisit their valuations. A remarkable run CareDx has been one of the market's best-performing health care stocks this year. The shares have gained about 357% year to date and nearly 492% over the past 52 weeks, rising from a low of about $14.27. The stock's 50-day moving average was about $59, while its 200-day average was about $33, underscoring the scale of the rally. The shares trade at about 36 times trailing earnings. Risks remain Despite the strong results, the stock's steep rise leaves it vulnerable to volatility. CareDx has a beta of about 2.4, meaning its shares tend to swing much more than the overall market. Investors will be watching whether the company can maintain its growth pace as it integrates Naveris and expands into oncology, as well as any changes to reimbursement for its tests, which have been a key factor for diagnostics companies. For now, the third-quarter results have given investors fresh reasons to bet on CareDx's transformation into a broader precision medicine company. MEET IBT NEWS FROM BELOW CHANNELS

CareDx CDNA soars after earnings beat and guidance hike. TIM BOHEN - UPDATED OCT. 30, 2026, 3:04 PM ET Summarize this article CareDx Inc. stocks have been trading up by 19.13 percent after upbeat transplant diagnostics coverage sparked renewed investor optimism. Key takeaways. * Q3 revenue near $139M-$139.4M smashed the roughly $122M consensus, powered by Transplant strength, scaling Specialty Oncology, and pipeline progress. * Profitability jumped, with GAAP EPS at $0.35 and adjusted EPS at $0.70, a sharp lift from last year's $0.03. * Full-year 2026 revenue guidance was raised to $520M-$530M and adjusted EBITDA to $90M-$100M, both well above prior targets and Street expectations. * Canaccord and BTIG lifted price targets to $80 and $81 while keeping Buy ratings, flagging strong fundamentals and room for further growth in CDNA. * Fresh AlloSure Kidney and AlloSure Plus data from ASN Kidney Week 2026 reinforced clinical strength, showing fewer biopsies and strong rejection prediction under updated Banff 2024 criteria. Live Update At 15:03:31 EDT: On Friday, October 30, 2026 CareDx Inc. stock [NASDAQ: CDNA] is trending up by 19.13%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below. Quick financial overview. CDNA has shifted from a quiet grinder to a clear momentum name. Over the last few weeks, CareDx climbed from around $64 on 2026/10/16 to $85.20 on 2026/10/30. That is a strong trend, not a random pop. The big acceleration hit right after earnings, with CDNA jumping from a 10/29 close of $71.52 to a high near $90.87 on 10/30 before settling in the mid-$80s. Intraday action on the latest session shows classic momentum behavior. CDNA opened around $80.61, ripped quickly into the high $80s and tagged $90.87, then consolidated mostly between $84 and $88. For short-term traders, that's a wide intraday range with plenty of liquidity and clean scalping opportunities. Under the hood, CareDx is not just a story stock. Key ratios show a gross margin above 70% and healthy cash flow metrics, backed by low leverage and a current ratio above 4. CDNA's recent quarter delivered operating revenue of about $139.4M and net income near $19.3M, showing the business is scaling. For traders, that combination of earnings power, guidance strength, and technical momentum makes CDNA a name to keep on the screen, while always respecting risk and volatility. Why traders are watching CDNA right now. CDNA is on the radar because the company finally lined up all three pillars momentum traders care about: a big earnings beat, bullish guidance, and analyst upgrades. CareDx reported Q3 revenue around $139M-$139.4M against expectations near $122M. That is a serious beat in the diagnostics space. CDNA's Q3 GAAP EPS jumped to $0.35 from $0.03 a year ago, and adjusted EPS printed at $0.70, signaling that CareDx is not just growing sales; it's converting growth into real profits. Management then doubled down with aggressive 2026 outlooks. CareDx lifted its revenue guidance to $520M-$530M, well ahead of the roughly $495M Street view and prior $490M-$500M range. It also boosted 2026 adjusted EBITDA guidance to $90M-$100M from $66M-$78M. When a company pushes revenue and earnings expectations higher at the same time, traders pay attention. It often forces analysts to chase estimates upward and can support a higher valuation for CDNA. The Street's reaction backed that view. Canaccord raised its price target on CareDx to $80 from $65, calling the stock undervalued with strong fundamentals. BTIG took its target from $74 to $81 while keeping a Buy rating, leaning on solid growth in life science and diagnostic tools. Those target hikes give momentum traders a visible "story" to trade around. On top of numbers, CareDx delivered new data at ASN Kidney Week 2026. Multiple independent studies showed AlloSure Kidney and AlloSure Plus reduce the need for invasive biopsies and still strongly predict rejection risk, even with updated Banff 2024 criteria. That clinical validation supports the long-term demand story behind CDNA's transplant testing franchise, reinforcing why the market is willing to reward the stock after strong Q3 results. Conclusion. For active traders, CDNA now looks like a textbook example of how strong fundamentals can light a fire under a chart. CareDx delivered big Q3 revenue upside, with about $139M-$139.4M versus roughly $122M expected, and drove GAAP EPS to $0.35 and adjusted EPS to $0.70. Then it raised 2026 revenue guidance to $520M-$530M and boosted adjusted EBITDA goals to $90M-$100M. That one-two punch shifted the narrative from "promising" to "executing." Analysts responded, with Canaccord and BTIG lifting price targets to $80 and $81 and reaffirming their bullish stances on CDNA. Meanwhile, new AlloSure Kidney data from ASN Kidney Week 2026 underlined CareDx's edge in transplant testing, reducing biopsies while maintaining strong prediction power under the newer Banff 2024 framework. That kind of science-backed moat matters when traders assess whether the revenue ramp is sustainable. From a trading perspective, CDNA's recent spike from the $60s into the mid-$80s demands respect. There is clear momentum, but also real volatility. As Tim Sykes likes to say, "The market rewards prepared traders, not hopeful gamblers." The same mindset is echoed in the pre-market routine championed by many educators; as Tim Bohen, lead trainer with StocksToTrade says, "Preparation is half the trade. By the time the bell rings, my decisions are nearly made." For anyone tracking CDNA, that means studying the earnings, guidance, clinical story, and the chart - and always having a plan to cut losses fast if the trend breaks. This analysis is for educational and research purposes only, not advice. This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action. Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead. Once your watchlist is set, take the next step and trade with confidence using StocksToTrade's robust platform. Don't miss out - grab your 14-day trial for just $7 and experience the edge you need to thrive in today's fast-paced markets. Wall Street is legally banned from these stocks. Sixteen analysts cover a stock like Apple. Zero cover a $2 stock with a $40 million market cap, and it's not by choice. Most hedge funds and pension funds have internal mandates that block them from buying anything under a certain size. Trader Tim Sykes built a simple scanner that hunts exactly that corner of the market, the one institutions can't legally enter.